A peer support community, independent and not for sale. Since February 2024.

GLP CircleA peer support community

starting

What to expect in the first twelve weeks

A week-by-week orientation to the steepest part of the curve, built from what several hundred members reported and what the trial safety tables show.

10 min read1.3k wordsUpdated 2 July 2026Reviewed by Esi

A warning about timelines

Every timeline you read about these medicines, including this one, is a composite. It is made by flattening several hundred different experiences into a shape, and the shape is useful for orientation and useless as a prediction. Members who compared themselves week by week against a timeline generally report that it made them anxious rather than informed.

So read this the way you would read a note about what the weather is usually like in a country you are visiting. Bring a coat. Do not be alarmed by sunshine.

One structural thing worth knowing first: because these drugs accumulate over several weeks and because you step up the dose during that period, the first twelve weeks contain two separate patterns laid on top of each other. There is the drug building to a steady level, and there is the small repeat of early symptoms that many people get in the days after each increase. When people say week seven was worse than week four, it is usually because week seven was three days after a step.

Weeks one and two

Quieter than most people fear. A common report in just-starting is nothing much at all, followed by a worry that the injection failed. It did not; blood levels are still climbing.

What does show up early for some people: a mild headache in the first couple of days, which in this community turns out to be fluid intake more often than not — see headaches and hydration. A slightly odd fullness after a normal-sized meal. Some burping. A day of feeling washed out.

Also, frequently, an emotional reaction nobody warns you about. Several members describe the first week as unexpectedly sad or unsettling — a sense of having handed something over to a chemical, or grief about the years before, or plain fear. Bea in Dublin wrote in her journal that she cried on the Tuesday and could not have told you why. That is a normal first fortnight and it is not a side effect you need to fix.

Practical things to get in place now rather than later: a sharps bin, a habit around fluid, and a two-line note after each dose. If constipation has ever been an issue for you, this is the week to raise it, not week six.

Weeks three to six

This is usually where the medicine announces itself.

Appetite change becomes unmistakable for most people. Portions that were normal become too much halfway through. Some people find whole categories of food have gone strange — coffee, meat, anything fried, anything sweet. Taste change is common and under-reported and it will unsettle you if you are not expecting it.

Nausea, if you get it, tends to be worst in the two or three days after a dose and to fade across the week. In STEP 1 (Wilding, NEJM, 2021) nausea was reported by roughly four in ten people on semaglutide 2.4 mg compared with roughly one in four on placebo, and it was mostly mild to moderate and mostly early. That placebo figure is worth sitting with: a quarter of people reported nausea on a dummy injection, which tells you something about how much of early symptom-reporting is the ordinary noise of being a body.

Constipation arrives in this window for a lot of people and is the single most common thing members wish they had handled sooner. There is a whole unglamorous guide: read it before you need it.

Also common: reflux, burping that surprises everyone within earshot, and the sulphur-scented variety that has its own guide because members asked for one.

Weeks six to twelve

Two things dominate the circle conversation in this stretch.

The first is fatigue. It is extremely common, it is discussed far less than nausea, and it frightens people because it has no obvious cause. Some of it is likely reduced intake, some is fluid, some is disrupted sleep from reflux, and some is not explained. Fatigue in the first months covers what to look at and, importantly, which causes of tiredness are worth a blood test rather than a shrug.

The second is stranger and harder to name: the psychological adjustment to not wanting food. For people who have spent decades in a running negotiation with appetite, the quiet is not automatically pleasant. Members describe boredom, a loss of something to look forward to, and occasionally a real grief. Jonah, who holds our recovery-aware circles, is clear that this deserves attention rather than being filed under a win — see food noise, what we mean by it.

Physically, many people find symptoms are settling by now. Others hit their worst fortnight at week nine. Annika in Stockholm nearly stopped in month four and says so in circle regularly, because month four is when the people who only read success stories start to feel like the exception.

What tends to change first

We do not do numbers on this site, and the change members mention first is usually not a number anyway. Things that come up again and again in milestones during the first twelve weeks:

  • Sleeping through the night, or snoring less, or a partner saying so.
  • Stairs. Specifically the third flight, or the bit at the top.
  • Ankles at the end of a day.
  • Blood pressure at the pharmacy machine, which several members check obsessively and are then pleased about.
  • Joint pain, particularly knees, easing before anything else is noticeable.
  • Sitting comfortably in a plane seat, a cinema seat, a booth in a restaurant.
  • Blood glucose readings steadying, for members with type 2 — often the very first thing, and often within weeks.

And for some people, in twelve weeks: not much yet. That is a real outcome too, it does not mean the medicine has failed, and it is the reason the plateau circle has members in month three.

What to raise with your clinician

Bring the pattern, not the anecdote. The sentences that make a short appointment work are the ones with days and durations in them.

  • Which days after your dose are difficult, and what happens on them.
  • Whether you are managing fluids, and whether you have gone a day without.
  • Constipation, in actual detail, including how long. People are shy about this and then end up in an out-of-hours appointment.
  • Anything you have taken for symptoms, including things bought over the counter.
  • Whether you are on insulin or a sulfonylurea, and what your readings have done — this is the one situation where hypoglycaemia is a live concern.
  • Any old condition that has flared: gallbladder history, reflux, an eating disorder history, migraine.

Talking to your GP when time is short is the practical companion to this, and the questions guide is worth printing.

What not to conclude from twelve weeks

Not much, honestly, and that is the most useful thing this guide can say.

Twelve weeks is not long enough to know how you will respond, because in most protocols you have only recently reached a maintenance dose. It is not long enough to know whether your side effects are permanent, because most early ones are not. And it is nowhere near long enough to draw conclusions about the things people worry about at 2am — the trials that speak to those questions ran for 68 and 72 weeks and beyond, and even they stop long before your life does.

What twelve weeks is long enough for is learning your own pattern: which days are hard, what helps, what a bad fortnight feels like from the inside and that it ends. That knowledge is worth more than any timeline, including this one, and you can only get it by living through the weeks and writing a little of it down.

Sources

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. (STEP 1 — nausea approximately 44% vs 28% on placebo; adverse events mostly mild-to-moderate and early)
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. (SURMOUNT-1 — gastrointestinal adverse events largely during escalation)
  3. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. (SELECT)

We name the trial, the journal and the year, because vague confidence is how people get hurt.

Read next

starting

Starting out: a kind orientation

What we would say to you across a kitchen table on your first week — what these medicines are, what the early months tend to look like, and what is not yet known.

9 min · reviewed by Esi · updated 12 Jun 2026

starting

Titration: why slow is kind to you

What stepping up a dose is for, what the label schedule is and is not, and how members have had the conversation about going slower with their prescriber.

9 min · reviewed by Tomás · updated 24 Apr 2026

symptoms

Nausea, honestly

Why nausea happens on these medicines, how common it really was in the trials, what several hundred members have found helps, and where it stops being ordinary.

9 min · reviewed by Tomás · updated 18 Apr 2026

symptoms

Fatigue in the first months

The symptom nobody warns you about. What is likely behind early tiredness, which causes deserve a blood test, and how members kept a life going through it.

9 min · reviewed by Kiki · updated 5 Jun 2026

symptoms

Constipation: the unglamorous guide

The symptom members most wish they had dealt with early. What causes it on these medicines, what has helped, what a pharmacist can offer, and when it stops being routine.

9 min · reviewed by Tomás · updated 8 May 2026

symptoms

When a symptom needs a clinician

The short list this community keeps: the symptoms that mean seek urgent care today rather than asking a forum. Written to be read once now, before anything is wrong.

9 min · reviewed by Tomás · updated 8 Jul 2026